Classifications: hormone and synthetic substitute; antidiabetic agent; insulin rapid-acting; Therapeutic: antidiabetic; insulin rapid-acting
Prototype: Insulin injection
Pregnancy Category: B
Insulin lispro of recombinant DNA origin is a human insulin that is a rapid-acting, glucose-lowering agent of shorter duration
than human regular insulin. It lowers blood glucose levels by increasing peripheral glucose uptake, especially by skeletal
muscle and fat tissue, and by inhibiting the liver from changing glycogen to glucose.
It lowers blood glucose levels and inhibits liver from changing glycogen to glucose.
Treatment of diabetes mellitus.
During episodes of hypoglycemia or in patients sensitive to any ingredient in the formulation; intravenous administration.
In insulin-resistant patients, hyperthyroidism or hypothyroidism; older adults, renal or hepatic impairment; children, pregnancy
(category B), lactation.
Route & Dosage
|Diabetes Mellitus (type 1)
Adult: SC 510 U 015 min a.c. (dose adjustments based on blood glucose determinations)
- Give 015 min before meals.
- Note: May be given in same syringe with longer-acting insulins but absorption may be delayed.
Adverse Effects (≥1%)
See INSULIN INJECTIONS, REGULAR
See INSULIN INJECTION, REGULAR
Rapidly absorbed from IM and SC injection sites. Onset:
<15 min. Peak:
0.51 h. Duration:
34 h. Distribution:
Throughout extracellular fluids. Metabolism:
Metabolized in liver with some metabolism in kidneys. Elimination:
<2% excreted in urine. Half-Life:
Biologic, up to 13 h.
(see INSULIN INJECTION, REGULAR)
Assessment & Drug Effects
- Assess for hypoglycemia from 1 to 3 h after injection.
- Assess highly insulin-dependent patients for need for increases in intermediate/long-acting insulins.
Patient & Family Education
- Note: Risk of hypoglycemia is greatest 13 h after injection.